pharmaphorum

Genmab ends lung cancer drug development

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

First breathing 'lung-on-chip' developed using genetically identical cells

Researchers at the Francis Crick Institute and AlveoliX have developed the first human lung-on-chip model using stem cells ...
Pharmaceutical Technology on MSN

Genmab shelves Phase III lung cancer candidate

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.
Emirates News Agency on MSN

First human 'lung-on-chip' model developed using stem cells from single donor

Researchers at the Francis Crick Institute and AlveoliX have developed the first human 'lung-on-chip' model using genetically identical cells derived from stem cells taken from a single donor.The ...
News-Medical.Net on MSN

First human 'lung-on-chip' model developed using stem cells from a single donor

Researchers at the Francis Crick Institute and AlveoliX have developed the first human 'lung-on-chip' model using stem cells ...

Restoring healthy protein form revives blood vessel growth in premature infant lungs

A UCLA-led research team has discovered a molecular switch that determines whether tiny blood vessels in premature infants' ...

Aravallis, a new turn in the ecology battle

There are some twists in the legal battle to save the Aravalli Hills. In a surprise development, on 20 November, the Supreme ...
Interesting Engineering on MSN

Scientists build first breathing 'lung-on-chip' model using only one person's cells

For the first time, a breathing lung model has been made using cells from only one person. Announced on January 1, the ...
pharmaphorum

AZ's ATR inhibitor ceralasertib flunks lung cancer test

"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...
PharmTech

A Year of Advancements in the Treatment of Cancer

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

Harvard study finds one-third of Delhi’s PM2.5 is ammonium sulfate: What is it and how harmful is it for human health

A big new study, with researchers from Harvard and CREA, just uncovered something troubling about Delhi’s air: almost a third ...